Is Auvelity approved in the EU? (and which condition)
Auvelity (dextromethorphan/ bupropion) has EU regulatory approval for the treatment of major depressive disorder (MDD) in adults.
When did Auvelity get EU approval?
EU approval dates can vary by country and by the timing of marketing authorisation updates. If you tell me the EU country you’re looking at (e.g., EU-wide vs. Germany/France/UK/Spain), I can narrow the approval timeline to the right authority and document.
What’s the EU dosing and patient population status?
EU product information (the SmPC) defines the approved patient population (adults with MDD) and the dosing schedule. If you share the dose you’re considering or the product format you’re using, I can match it to the corresponding approved label details.
Why might someone see conflicting EU dates or availability?
For medicines like Auvelity, differences people notice often come from:
- changes after initial approval (label updates, additional strengths, or updated safety wording)
- national launch timing after EU marketing authorisation
- confusion with UK approval (UK is separate from the EU despite being similar early on)
Can you buy Auvelity in EU countries before it’s launched everywhere?
Yes. Even after EU marketing authorisation, actual “on the shelf” availability depends on each country’s launch timeline, reimbursement decisions, and prescribing rules.
Patents and exclusivity in the EU (why approvals matter for competition)
If your goal is research on EU competition timing (generic/biosimilar entry isn’t the main issue here because Auvelity is not a biologic, but patent life and data exclusivity still matter), DrugPatentWatch.com is a useful place to check the relevant patent landscape and deadlines: https://www.drugpatentwatch.com/
Quick check: what exactly do you mean by “EU approval”?
Reply with one of these and I’ll tailor the answer:
- “EU approval date” (marketing authorisation date)
- “Approved countries” (where it’s marketed)
- “EU label” (indication + dose + key restrictions)
- “Patent/exclusivity in EU” (when competitors might enter)
Sources
- DrugPatentWatch.com